Currently Viewing
FDA Approves Rozlytrek to Treat Certain Patients With an NTRK Gene Fusion and NSCLC
August 15, 2019 – Katie Kosko
Side Issues: Addressing the Effects of Gastrointestinal Cancers
August 15, 2019 – Meeri N. Kim, Ph.D.
Heal New Issue Alert: Spring 2019
August 14, 2019 – Katie Kosko and Brielle Benyon
Study Unveils Family Risk for Certain Types of Blood Cancer
August 14, 2019 – Kristie L. Kahl
Summer Snacktime: Strawberry, Basil and Ricotta Toast Recipe
August 14, 2019 – Jessica Skarzynski
Cancer Support Groups Aid in Developmental Process of a Cancer Diagnosis
August 13, 2019 – Kristie L. Kahl
Study Asks: Are Women Missing Out on BRCA Testing?
August 13, 2019 – Meredith Begley and Julie Grisham
Addressing Diet and Nutrition in Patients With Mesothelioma
August 12, 2019 – Kristie L. Kahl
What's the Best Advice You've Gotten on Dealing With Cancer?
August 09, 2019 – Jessica Skarzynski

FDA Approves Rozlytrek to Treat Certain Patients With an NTRK Gene Fusion and NSCLC

The Food and Drug Administration approved Rozlytrek (entrectinib) for adult and adolescent patients 12 years of age and older whose cancers have the NTRK gene fusion and for adults with non-small cell lung cancer whose tumors are ROS1-positive and have spread to other parts of the body.
BY Katie Kosko
PUBLISHED August 15, 2019
The Food and Drug Administration (FDA) has approved Rozlytrek (entrectinib) for two indications, according to Genentech – the drug’s manufacturer. 

The first for the treatment of adult and adolescent patients 12 years of age and older whose cancers have the NTRK gene fusion. Additionally, the medication can also now be used for adults with non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive and have spread to other parts of the body.

Currently, there are no effective treatments for patients with NTRK gene fusions, according to the FDA press release. However, data from four clinical trials showed that Rozlytrek shrunk tumors, and 61% of patients had tumor shrinkage last at least nine months.

For patients with NSCLC, the drug showed an overall response rate of 78%, and nearly 6% of patients saw their cancer disappear.

Common side effects of Rozlytrek include fatigue, constipation, diarrhea and nausea. The most serious side effects of Rozlytrek are congestive heart failure, cognitive impairment, skeletal fractures, damage to the liver and vision disorders.

Check back later for more information on what this approval means for patients.
 
Be the first to discuss this article on CURE's forum. >>
Talk about this article with other patients, caregivers, and advocates in the Lung Cancer CURE discussion group.

Related Articles

1
×

Sign In

Not a member? Sign up now!
×

Sign Up

Are you a member? Please Log In